Clinical trials: Memory Impairment
Age-Related Memory Disorders
A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)
The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI).
- Trial name
- NCT00109564
- Testing
- ispronicline (nicotinic acetylcholine receptor agonist)
- Where
- 15 sites in United States
- Volunteers
- 174 people, healthy volunteers welcome
- Sponsor
- Targacept Inc.
Age-Associated Memory Impairment
Tricaprilin In Age-Associated Memory Impairment
The purpose of this study is to determine whether tricaprilin, a compound that increases energy availability in the brain, improves memory in older adults with "normal" loss of memory abilities since early adult life.
- Trial name
- NCT00355550
- Testing
- Tricaprilin
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- Cerecin
Memory Impairment, Age-related Cognitive Decline
Development of an Innovative Health Ingredient From Marine By-products for the Healthy Aging
This interventional, randomised, placebo-controlled and double-blind study aims to evaluate the effect of a dietary supplementation with a blue fish hydrolysate derived from marine by-products, containing peptides and n-3…
- Trial name
- BRAINBOOSTER (NCT04910399)
- Testing
- Blue fish hydrolysate
- Where
- 2 sites in France
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Abyss Ingredients
Craniocerebral Injury
Study on Clinical Effectiveness of L-Oxiracetam Injection
A randomized, double-blind, positive drug/placebo parallel controlled, multicenter, phase III clinical trial of L-oxiracetam injection to improve memory and cognitive Impairment in patients with craniocerebral injury.
- Trial name
- NCT04205565
- Testing
- Test group: L-oxiracetam Injection, Control group: Oxiracetam Injection
- Where
- China
- Volunteers
- 591 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Dementia, Mild Cognitive Impairment
HOme-based Brain Monitoring With a GARment-EEG to Study Cognitive Decline in the Aging Population
This study will investigate the validity of the HOGAR EEG/PSG monitoring kit designed by Bitbrain as a tool for characterizing and assessing cognitive function in older adults, as well as for detecting and predicting cognitive…
- Conditions
- Dementia, Mild Cognitive Impairment, Dementia Alzheimers, Dementia, Mixed
- Trial name
- Hogar (NCT06993207)
- Testing
- Home Lab
- Where
- Spain
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Bitbrain
Cognition, Cognitive Performance
A Clinical Trial to Investigate the Safety and Efficacy of AP-Brain on Cognitive Performance at Varying Dosages in Healthy Middle-aged and Older Adults With Self-reported Memory Problems
The goal of this clinical trial is to investigate the safety and efficacy of AP-Brain on cognitive performance at varying dosages in healthy middle-aged and older adults with self-reported memory problems.
- Trial name
- NCT07388043
- Testing
- AP-Brain (1g), AP-Brain (3g), AP-Brain (5g)
- Where
- 2 sites in Canada
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Rousselot BVBA
Alzheimer's Disease
Acute Effects Of Donepezil On Brain Perfusion And Memory In Subjects With Cognitive Impairment And Mild Alzheimer's Disease
The study hypothesizes that donepezil will have a positive impact on brain blood flow deficits in subjects with memory deficits and/or mild dementia and that improvements in brain blood flow will be accompanied by improvements in…
- Trial name
- NCT01082965
- Testing
- Donepezil
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pfizer
Alzheimer's Disease, Mild Cognitive Impairment
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
The purpose of this study is to assess the performance of AclarusDx™, an investigational blood test detecting gene expression information, and intended to help physicians in making an Alzheimer's Disease diagnosis in patients…
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Vascular Dementia, Fronto-temporal Dementia
- Trial name
- NCT01465360
- Where
- 3 sites in United States
- Volunteers
- 160 people
- Sponsor
- Exonhit
Alzheimer Disease, Cognition Disorders
Investigation Into Delay to Diagnosis of Alzheimer's Disease With Exelon (InDDEx)
This phase IIIb trial is a prospective, randomized, double-blind, placebo-controlled, 36-month study comparing the length of time of progression from mild cognitive impairment (MCI) to a clinical diagnosis of Alzheimer's disease…
- Trial name
- NCT00000174
- Testing
- Rivastigmine
- Where
- 15 sites in United States
- Sponsor
- Novartis
Cognitive Impairment, Brain Fog
A Clinical Trial to Evaluate the Effects of a Supplement on Cognitive Performance
This study evaluates the effects of the Xula Herbs Mind Food supplement on cognitive performance in adults aged 25-70 who report difficulty concentrating, memory challenges, brain fog, and low productivity.
- Conditions
- Cognitive Impairment, Brain Fog, Memory Difficulties, Difficulty Concentrating
- Trial name
- NCT07742605
- Testing
- Xula Herbs Mind Food Supplement
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Xula Wellness LLC
Alzheimer Disease, Alzheimer Dementia
Alzheimer's Autism and Cognitive Impairment Stem Cell Treatment Study
The purpose of the study is to evaluate the use of autologous Bone Marrow Derived Stem Cells (BMSC) as a means to improve cognitive impairment as occurs in Alzheimer's Disease and other dementias and to improve behavior and…
- Conditions
- Alzheimer Disease, Alzheimer Dementia, Vascular Dementia, Lewy Body Disease
- Trial name
- ACIST (NCT03724136)
- Testing
- Intravenous Bone Marrow Stem Cell (BMSC) Fraction, Intranasal Topical Bone Marrow Stem Cell (BMSC) Fraction, Near Infrared Light
- Where
- 3 sites in United States, United Arab Emirates
- Volunteers
- 100 people
- Sponsor
- MD Stem Cells
Memory Impairment, Alzheimer's Disease
Roflumilast and Donepezil to Reverse Scopolamine Induced Cognitive Deficits in Healthy Adults
The purpose of this study is to determine whether scopolamine-induced cognitive impairment is attenuated by the administration of roflumilast in combination with donepezil.
- Trial name
- NCT02051335
- Testing
- Roflumilast, Donepezil, Scopolamine
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Alzheimer's Disease, Dementia
Safety and Efficacy of High Dose, Rapid Titration Galantamine in Patients With Alzheimer's Disease
The purpose of this study was to determine the safety and effectiveness of a relatively high dose of galantamine, 32 mg /day in a three-times daily dosage, compared with placebo in treating patients with Alzheimer's disease.
- Trial name
- NCT00338117
- Testing
- Galantamine hydrobromide
- Volunteers
- 554 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Age-Associated Memory Impairment (AAMI)
HT-0712 vs. Placebo in Subjects With Age-Associated Memory Impairment (AAMI)
This is a Phase 2 randomized, multicenter, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy of HT-0712 in improving memory and cognitive performance in subjects with Age-Associated Memory Impairment…
- Trial name
- PRIME (NCT02013310)
- Testing
- HT-0712
- Where
- 16 sites in United States
- Volunteers
- 119 people
- Sponsor
- Dart NeuroScience, LLC
Age-associated Memory Impairment
Effect of BrainPhyt High Dose on Cognitive Function in Healthy Older Individuals
The purpose of this study is to evaluate if BrainPhyt, a microalgae based ingredient may affect cognitive function parameters in older healthy individuals with evidence of age-related cognitive decline.
- Trial name
- PHAEO-FOUR (NCT05759910)
- Testing
- Brainphyt high dose
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Microphyt
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC
Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI
Auditory Stimulation During Sleep to Enhance Long-Term Memory in Amnestic MCI
This study aims to evaluate the efficacy and safety of Elevvo AudiStim, a sleep auditory stimulation device, as a symptomatic treatment for patients with amnestic mild cognitive impairment (aMCI).
- Conditions
- Mild Cognitive Impairment (MCI), Amnestic Mild Cognitive Impairment - aMCI, Alzheimer or Mild Cognitive Impairment
- Trial name
- NCT07402590
- Testing
- Auditory Stimulation
- Where
- Spain
- Volunteers
- 37 people
- Sponsor
- Bitbrain
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Healthy
A Study in Healthy Men to Test Whether BI 474121 Can Reverse the Memory Problems Caused by Ketamine
To investigate the effect of BI 474121 compared to placebo on ketamine-induced cognitive deficits to predict efficacy in patients with cognitive disorders.
- Trial name
- NCT05451095
- Testing
- BI 474121, Ketamine hydrochloride
- Volunteers
- healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Alzheimer Disease (AD)
A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to evaluate the safety and efficacy of a study drug that targets an abnormal protein in the brain found in people with Alzheimer's Disease (AD).
- Trial name
- NCT03518073
- Testing
- Zagotenemab
- Where
- 60 sites in United States, Canada and 1 more
- Volunteers
- 360 people
- Sponsor
- Eli Lilly and Company